PURCHASE, NY--(Marketwire - December 15, 2010) - Nutrition 21, Inc. (
Chromax® chromium picolinate is Nutrition 21's top selling nutritional supplement ingredient in the U.S. The formal approval of chromium picolinate for its use in both fortified food and "medical" food applications in the EU and will provide Nutrition 21 with additional opportunities for business expansion. William J. Levi, Vice President - Ingredients for Nutrition 21, stated, "This is an exciting development for our Ingredients business. Expansion into the European Union is an important component of our growth strategy. We, along with our European distributor Ingredia, look forward to pursuing opportunities with food companies."
James Komorowski, Vice President, Research & Development at Nutrition 21, commented, "The safety review was extensive and included a review of Nutrition 21's safety data on Chromax chromium picolinate, our manufacturing and product specifications, and the long-term, high-dose, toxicity studies independently conducted by the U.S. National Toxicology Program." In total, the safety review included over 140 references. "The expert opinion on the safety of chromium picolinate and the extensive scientific support is consistent with the high quality standards Nutrition 21 stands behind when offering our premium ingredients to customers and consumers," added Mr. Komorowski.
European Food Safety Authority (EFSA)
The European Food Safety Authority (EFSA) is the keystone of European Union (EU) risk assessment regarding food and feed safety. In close collaboration with national authorities and in open consultation with its stakeholders, EFSA provides independent scientific advice and clear communication on existing and emerging risks.
About Nutrition 21
Nutrition 21, Inc. (
Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2010. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.
Contact Information:
Company Contact:
James Komorowski, M.S., C.N.S.
Vice President
914-701-4500
Investor Contact:
Alan Kirschbaum
Chief Financial Officer
914-701-4500